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Objectives: In patients diagnosed with incidental gallbladder cancer (GC), the benefit and optimal extent
of further surgery remain unclear. The aims of this study were to analyse outcomes in patients who
underwent liver resection following a diagnosis of incidental GC and to determine factors associated with
longterm survival.
Methods: A retrospective analysis of patients diagnosed with incidental GC between June 1999 and
June 2010 was performed. Data covering demographics, clinical and surgical characteristics and local
pathological stage were analysed.
Results: A total of 24 patients were identified. All patients underwent a resection of segments IVb and
V and lymphadenectomy. Histological examination revealed residual disease in 10 patients, all of whom
presented with recurrent disease at 3–12 months. Overall 5-year survival was 53%. Increasing T-stage
(P < 0.001), tumour–node–metastasis (TNM) stage (P = 0.003), and the presence of residual tumour in the
resected liver (P < 0.001) were all associated with worse survival.
Conclusions: Aggressive re-resection of incidental GC offers the only chance for cure, but its efficacy
depends on the extent of disease found at the time of repeat surgery. The presence of residual disease
correlated strongly with T-stage and was the most relevant prognostic factor for survival in patients
treated with curative resection.
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Introduction
Gallbladder cancer (GC) is the sixth most common gastrointesti-
nal malignancy worldwide.1 In Argentina it predominates in the
Province of Salta with an incidence of 6.7/100 000 population.2
The prognosis is dismal as the majority of patients are diagnosed
in advanced stages of malignancy. It is estimated that only 15% of
GC patients will survive for >5 years after diagnosis.3 Longterm
survival has been reported mostly in patients with early tumours
that are diagnosed incidentally on pathological examination of
cholecystectomy specimens.4 Radical surgery for GC has been
associated with the likelihood of longterm survival.5,6 This applies
not only in cases of per primum surgery, but also in the revision of
radical surgery for incidental GC.6,7 The rationale for performing
revision surgery in patients who have undergone simple cholecys-
tectomy for invasive GC is based on the premise that as the
tumour stage (T-stage) increases, so does the chance that residual
disease will be found in the gallbladder fossa, as well as in the
regional lymph nodes.6,7 In the era of laparoscopic cholecystec-
tomy, the identification of incidental GC has dramatically
increased and it now constitutes the most common presentation
of this disease.8,9 Several aspects of the surgical approach are still
under debate, such as the extent of liver resection and lym-
phadenectomy, the need for common bile duct resection and the
concomitant performance of a pancreatoduodenectomy.10,11 The
therapeutic efficacy and appropriate extent of the resection
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remain unclear.12 No difference in longterm survival between
patients undergoing one and those undergoing more than one
operation has been reported.13
The objectives of this study were to analyse the results of liver
resection in patients with incidental GC and to determine factors
associated with longterm survival.
Materials and methods
A retrospective analysis was performed of data for patients referred
to theHospital Dr CArgerich with a diagnosis of GC between June
1999 and June 2010. Patients were identified from the Liver and
Transplant Division’s prospective computerized database. Preop-
erative assessment included clinical history, routine blood tests,
carbohydrate antigen 19-9 (CA 19-9), transabdominal ultrasound
and computed tomography (CT) of the chest, abdomen and pelvis
with enhanced triphasic contrast of the liver.
A total of 60 patients with GC were identified; 40 (67%)
patients had presented with incidental tumours diagnosed by
subsequent pathological examination. The surgical approach
involved resection of liver segments IVb and V with supraduode-
nal lymphadenectomy. Operative mortality included any death
attributed to liver resection and all deaths occurring within
30 days of partial hepatectomy. Explanted specimens were
reviewed by a single experienced liver pathologist. Involvement of
liver, lymph nodes and port sites, surgical margins, and vascular
and perineural invasion were assessed. A curative resection (nega-
tive margin, R0) was defined as the complete removal of any
clinically evident tumour lesion(s) with negative pathological
margins. Any infiltration of the resection margin by tumour cells
in the histological specimen was defined as an R1 resection.
Residual disease was defined by findings of microscopic liver
involvement, positive nodes or positive port sites in the pathologi-
cal examination after radical surgery. Clinical staging of disease
was performed according to the 7th edition of the American Joint
Committee on Cancer (AJCC) staging system.14 Chemotherapy
was given in patients with residual disease. Postoperative
follow-up was performed by physical examination and CT at
6-month intervals.
Data on demographic features, clinical characteristics, local
pathological stages, surgical procedures, morbidity, pathological
features and factors for longterm survival were analysed.
All statistical analyses were performed using spss Version 15
(SPSS, Inc., Chicago, IL, USA). Significance was calculated using
the chi-squared test and correlations were measured using cross
tabs. Survival curves were estimated with the Kaplan–Meier
method and compared using the log-rank test in statistical analy-
sis. P-values of < 0.05 were considered to indicate statistical sig-
nificance.
Results
Of the 40 patients with incidental GC, 24 were candidates for
curative treatment. Twenty of these 24 patients were female. The
mean age of the patients was 57.4 years (range: 38–78 years).
Twenty-two patients had been referred from other institutions.
Laparoscopic cholecystectomy had been performed in four
patients and open cholecystectomy in 20. Gallbladder cancer was
diagnosed at the time of cholecystectomy or after the procedure
on analysis of the pathological specimen in two and 22 patients,
respectively.
Pathological analysis of the gallbladder confirmed the T-stage
of the disease as T-stage Ib, II and III in one, 12 and 11 patients,
respectively.
At the time of referral (median 28 days, range: 0–150 days), 15
patients were found to be inoperable as a result of disease pro-
gression (n = 13) or refusal of surgical treatment (n = 2). Only one
patient was found to have disseminated peritoneal disease at lap-
arotomy. All non-resected patients subsequently presented with
disease progression in the liver parenchyma and died at
3–6 months.
All resected patients in this study were treated by laparotomy
and resection of liver segments IVb and V with an N1 lym-
phadenectomy. In the four patients who had undergone previous
laparoscopic cholecystectomy, port site resection was performed
at the time of laparotomy. No mortality was observed. Five
patients suffered perioperative morbidity. Median postoperative
stay was 5.5 days (range: 4–10 days).
Pathology
In 23 patients, the IVb–V liver resections were R0. Histological
examination revealed adenocarcinoma in all patients.Histopatho-
logical staging is shown in Table 1. Seventeen tumours were
reported as moderately differentiated. Positive lymph nodes were
identified in three patients. The median number of lymph nodes
dissected was three (range: 1–10 lymph nodes). Microscopic vas-
cular invasion and perineural invasion were each found in two
patients.Microscopic tumour involvement of the liver was present
in seven patients, all of whom had stage III disease.One of the four
patients who underwent port site resection was found to have
metastatic disease in the resected port site. Residual disease was
found in 10 of 24 patients; one of these patients had stage II
disease and nine had stage III disease (P < 0.001).
Survival
The median length of follow-up was 25 months (range:
6–132 months). Figure 1 summarizes overall survival in the 24
Table 1 Histopathological staging in 24 patients with incidental gall-
bladder cancer who underwent resection of liver segments IVb–V
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resected patients. Five-year overall survival by tumour–node–
metastasis (TNM) stage was 100% in stage II and 22.5% in stage
III disease (Fig. 2).Variables studied by statistical analysis to deter-
mine their relationship to survival are shown in Table 2. Four
patients presented with local recurrence (n = 3 in the liver, n = 1 in
lymph nodes; median time to recurrence: 7.5 months; range:
4–12 months) and six patients relapsed with metastatic disease
(median time to relapse: 6 months; range: 3–9 months), most
commonly in the peritoneum. Recurrence was found to increase
significantly according to T-stage. The only patient with a T-stage
Ib tumour died 6 months after surgery from gastrointestinal
bleeding without tumour recurrence. All patients with positive
lymph nodes, port site implants and microscopic involvement of
the gallbladder fossa died within 15 months. A significant differ-
ence in survival emerged in patients with non-residual disease
according to whether they had T-stage II (P = 0.002) or III
(P = 0.01) disease.
Discussion
Gallbladder cancer is the most common biliary tract tumour, but
remains a relatively infrequent gastrointestinal malignancy. The
rate of incidental presentation has increased in recent years and
this presentation predominates in Western countries.15 The 67%
rate of incidental presentation reported in the present study is
similar to those reported by institutions in the USA and Chile.16
Shih et al. reported a series of 53 patients with incidental GC
which demonstrated that a laparoscopic approach increased the
rate of early detection and longterm survival if patients were
treated in centres that regularly perform radical surgery for this
type of tumour.9 In the current study, the most common T-stage
was T-stage II, but only five patients had previously undergone
laparoscopic cholecystectomy. The low incidence of laparoscopy is
explained by the inclusion in the present study of a high percent-
age of patients referred from regional centres in Argentina that
continue to undertake a high proportion of conventional
cholecystectomies.
The definition of the optimal treatment for incidental GC is still
controversial. When it is feasible, radical re-resection offers the
only potential for cure, but there is debate over the selection of
patients for a second operation according to T-stage and the
extent of resection. In a recent US study in 4631 patients with GC,
only 2%were treated with the recommended surgery and only 5%
of patients with T-stage I–II disease underwent further surgery.5
Dismal results were related to the aggressive biology of this cancer
and advanced disease at presentation. Recently, 5-year survival
rates as high as 38% have been reported in patients undergoing
radical resection,17,18 which indicates that loco-regional recurrence
may be reduced with optimal surgical management. In the present
series, R0 resection was achieved in 96% of patients and the 5-year
survival rate was 53%, which is comparable with rates reported in
other series.18 However, a high proportion of patients with inci-
dental GC are not eligible for potentially curative re-resection, as
evidenced by the 35% of patients with disseminated disease who
did not undergo re-resection in the current study. Debate on the
appropriate extent of resection is ongoing.8 A Japanese study
found no statistical differences in survival or recurrence rates in
patients with T-stage II–III disease who underwent gallbladder
bed resection compared with segmentectomy IVb–V.19 Goetze and
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Figure 1 Five-year overall survival in 24 patients who underwent


















At risk, n:             
Stage II             10             10             10              10                10             10         
Stage III            11               6               4                4                 4               4 
Figure 2 Five-year overall survival in patients with tumour–node–
metastasis stage II and III disease
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for T-stage II tumours, resection of liver segments IVb–V seems to
be the minimum volume of resection required.20 It is the present
authors’ belief that segmentectomy IVb–V should be performed
because the procedure is associated with low morbidity and has
the advantage of removing micro-metastases in the drainage area
of the cystic vein.9,19,21,22 Resection of the laparoscopic port sites
has a staging purpose, but offers no advantage in patients with
confirmed implants that usually progress with peritoneal recur-
rence.8,13,23,24 A recent study found that port site resection was not
associated with improved survival or recurrence and concluded
that it should not be considered mandatory during definitive sur-
gical treatment.25 A role for laparoscopy in re-exploration and
resection for incidental GC has been advocated, but more defini-
tive prospective studies are needed.26
Previous studies have shown the presence of parenchymal
involvement in liver resections for incidental GC at rates of 20%
and 0%, respectively.21,27 In the present series, seven patients who
underwent re-resection were found to have residual disease in the
liver bed. In a multicentre study involving 115 patients who
underwent repeat surgery for incidental GC, residual tumour in
the liver bed was found in only 15% of patients, but this series
included a predominance (69%) of T-stage II patients.25 In a
recent report analysing the impact of accurate staging in GC, 38%
of residual disease in the gallbladder fossa was shown to occur in
incidental tumours.28 Tumour stage correlates with the likelihood
of residual disease in the liver and lymph nodes.28 Whether there
is any prognostic benefit from re-resection in patients with
residual disease is currently undetermined. In the present study, all
patients with residual disease died in <15 months. Other authors
have reported low survival rates, especially when residual disease
was located in the liver.15,25 Prognosis is also correlated with nodal
status and lymph node metastases have been reported as the most
frequent site of additional disease.25 Although a median of three
nodes per patient were dissected in the current study, only two
patients were found to have lymph node metastases. The findings
of a recent study by Ito et al.,28 showing that the number of lymph
nodes evaluated is critical for stratifying recurrence risk and
cancer-specific survival, are supported elsewhere.29–32 Radical
surgery of GC with positive lymph nodes can lead to longterm
survival in a subset of patients.25,33 The identification of patients
with potential residual disease will be crucial to improve survival
in incidental GC. It might be useful to use 18FDG-positron emis-
sion tomography (PET)-CT in the selection of patients.34,35 At
present, adjuvant chemotherapy has not been demonstrated to
provide any benefit in patients with residual disease.36
In the present series, patients with stage II disease appeared to
benefit most, achieving a 5-year survival rate of 100%, whereas
those reported elsewhere ranged from 61% to 91%.8,18 In a previ-
ous study of 443 radical operations for GC, the prognostic factors
of age, T-stage, lymph node involvement (N-stage), gender and
Table 2 Analysis of variables related to recurrence and survival in 24 patients with incidental gallbladder cancer who underwent resection
of liver segments IVb–V
Variable Patients, n Recurrence, n (%) P-value Survival, months, median
(range)
P-value
Age >65 years 5 3 (60%) 0.2 10 (6–55) 0.8
Age 65 years 19 6 (31%) 42 (6–132)
Positive lymph nodes 3 3 (100%) 0.01 10 (10–15) 0.2
Negatives lymph nodes 21 6 (28%) 42 (6–132)
Vascular invasion present 2 2 (100%) 0.05 11 (10–12) 0.05
Vascular invasion absent 22 7 (32%) 31 (6–132)
R0 resection 23 8 (35%) 0.1 31 (6–132) 0.4
R1 resection 1 1 (100%) 12
T-stage
Ib 1 0 0.01 6 0.001
II 10 1 (10%) 65 (15–132)
III 12 8 (66%) 10 (6–84)
Tumour–node–metastasis (TNM) stage
I 1 0 0.006 6 0.003
II 10 0 65 (31–132)
IIIa 9 5 (55%) 12 (6–84)
IIIb 2 2 (100%) 14.5 (10–15)
IVb 2 2 (100%) 8 (6–10)
Residual disease present 10 10 (100%) 0.001 10 (6–15) <0.001
Residual disease absent 14 0 65 (6–132)
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adjuvant radiotherapy were found to be associated with better
survival.3 The present analysis, which was limited to incidental
GC, showed that vascular invasion, tumour extension, TNM stage
and the presence of residual disease in resected specimens were
prognostic factors for survival. Similarly, in a study by Zaydfudim
et al. of 4048 US patients, tumour extension and nodal invasion
were identified as factors associated with longterm survival.37
In conclusion, the present study confirms that preoperative
T-stage and TNM-stage are important factors for determining
survival. Aggressive re-resection of incidental GC offers the only
chance for cure, but its efficacy depends on the extent of disease
found at repeat surgery. Residual disease was predominant in the
liver (29%), correlated strongly with T-stage and was the most
relevant prognostic factor for survival in patients treated with
curative resection. Future adjuvant therapies in this setting will be
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